$RNXT

RenovoRx, Inc.

CIK:0001574094|SEC Filings

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues	$ 909	$ 422	$ 1,472	$ 619
Cost of revenue	143	152	227	246
Gross profit	766	270	1,245	373
Operating expenses:
Research and development	1,200	1,426	2,428	3,068
Selling, general and administrative	2,915	1,522	5,635	3,093
Total operating expenses	4,115	2,948	8,063	6,161
Loss from operations	(3,349)	(2,678)	(6,818)	(5,788)
Other income (expense), net
Interest income, net	90	133	134	239
Loss of disposition of assets	(2)	0	(2)	0
Change in fair value of common warrant liability	350	(350)	254	234
Total other income (expense), net	438	(217)	386	473
Net loss	$ (2,911)	$ (2,895)	$ (6,432)	$ (5,315)
Net loss per share - basic	$ (0.06)	$ (0.08)	$ (0.15)	$ (0.16)
Net loss per share - diluted	$ (0.06)	$ (0.08)	$ (0.15)	$ (0.16)
Weighted average shares of common stock - basic	47,298,148	36,576,567	42,690,881	34,000,539
Weighted average shares of common stock - diluted	47,298,148	36,576,567	42,690,881	34,000,539

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (6,432)	$ (5,315)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	887	633
Non-cash lease expense	57	42
Change in fair value of common warrants classified as a liability	(254)	(234)
Depreciation expenses	6	2
Loss on disposition of assets	2	0
Changes in operating assets and liabilities:
Accounts receivable	(341)	(320)
Inventory	(194)	0
Prepaid expenses	9	(102)
Other current assets	64	15
Other non current assets	(200)	0
Accounts payable	48	85
Accrued expenses	(228)	(489)
Net cash used in operating activities	(6,576)	(5,683)
Cash flows from investing activities:
Purchase of property and equipment	(71)	(2)
Net cash used in investing activities	(71)	(2)
Cash flows from financing activities
Proceeds from common stock and pre-funded common stock warrants	10,000	12,102
Issuance cost of common stock upon private placement	(898)	(1,299)
Proceeds from exercise of common warrants	0	25
Proceeds from exercise of stock options	0	17
Net cash provided by financing activities	9,102	10,845
Net increase in cash and cash equivalents	2,455	5,160
Cash and cash equivalents:
Beginning of period	7,024	7,154
End of period	9,479	12,314
Supplemental disclosure of cash flow information:
Cash paid for income taxes	1	2
Cash paid for interest	6	7
Supplemental disclosure of non-cash investing activities
Purchase of property and equipment	19	0
Right-of-use assets obtained in exchange for modified operating lease obligations, net	$ 235	$ 0

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 9,479	$ 7,024
Accounts receivable	480	139
Prepaid expenses	315	324
Inventory	383	189
Other current assets	153	217
Total current assets	10,810	7,893
Operating lease right-of-use asset	368	190
Property and equipment, net	94	12
Other non current assets	200	0
Total assets	11,472	8,095
Current liabilities:
Accounts payable	866	799
Accrued expenses and other current liabilities	1,018	1,163
Total current liabilities	1,884	1,962
Common stock warrant liability	350	604
Operating lease liability, net of current portion	259	107
Total liabilities	2,493	2,673
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.0001 par value, 250,000,000 shares authorized at June 30, 2026, and December 31, 2025; 45,121,982 and 36,613,916 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	5	4
Additional paid-in capital	76,793	66,805
Accumulated deficit	(67,819)	(61,387)
Total stockholders' equity	8,979	5,422
Total liabilities and stockholders' equity	$ 11,472	$ 8,095